Xenon Pharmaceuticals Inc. XENE
NASDAQ · United States · Health Technology
$37.19-0.06 (-0.16%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award. 2026 Bloom Burton Award Winner Ian Mortimer, President and Chief Executive Officer of Xenon PharmaceuticalsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/6420/316465_7cc4242184cef922_001full.jpgIn the past..
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.Sherry Aulin is a finance executive with more than
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.